China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed.
Triastek utilizes a Melt Extrusion Deposition (MED) process for its drug 3D printing, while BASF specializes in Hot Melt Extrusion (HME) technology. This deep cooperation will leverage BASF’s extensive experience and technological expertise in polymer materials and drug solubilization. The partnership is set to expand Triastek’s polymer material database, enabling the identification of more suitable pharmaceutical excipients and formulations for 3D printing.
By combining their strengths, Triastek and BASF aim to provide robust support for the development of 3D drug printing, enhancing the formulation of pharmaceutical products and paving the way for innovative solutions in the industry.-Fineline Info & Tech
